Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
2.04/4.76
|
|
Enterprise Value
16.81B
|
| Balance Sheet |
|
Book Value Per Share
42.01
|
| Cash Flow |
|
Cash Flow Yield
0.06
|
| Income Statement |
|
Total Revenue
3.90B
|
|
Operating Revenue Per Share
17.68
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/11/15 01:08 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical,founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market. |

72.13 
